Feng Tiejun, Xie Fuda, Lee Leo M Y, Lin Zhiqiang, Tu Yifan, Lyu Yang, Yu Peiyao, Wu Jialin, Chen Bonan, Zhang Ge, Tse Gary M K, To Ka Fai, Kang Wei
Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, Sir Y.K. Pao Cancer Center, The Chinese University of Hong Kong, Hong Kong, China.
Institute of Digestive Disease, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Hong Kong, China.
Mol Cancer. 2025 Aug 8;24(1):213. doi: 10.1186/s12943-025-02419-2.
Cellular senescence is a double-edged sword in cancer biology, functioning as both a tumor-suppressive mechanism and a driver of malignancy. Initially, senescence acts as a protective barrier by arresting the proliferation of damaged or oncogene-expressing cells via pathways such as oncogene-induced senescence and the DNA damage response. However, persistent senescence-associated secretory phenotype and metabolic reprogramming in senescent cells create a pro-inflammatory, immunosuppressive tumor microenvironment, fueling cancer progression, therapy resistance, and metastasis. This comprehensive review systematically examines the molecular mechanisms of senescence across diverse cancers, spanning digestive, reproductive, urinary, respiratory, nervous, hematologic, endocrine, and integumentary systems, and elucidates its context-dependent roles in tumor suppression and promotion. We highlight groundbreaking therapeutic innovations, including precision senolytics, senomorphics, and combinatorial strategies integrating immunotherapy, metabolic interventions, and epigenetic modulators. The review also addresses microenvironment remodeling and cutting-edge technologies for dissecting senescence heterogeneity, epigenetic clocks for biological age prediction, and microbiome engineering to modulate senescence. Despite their promise, challenges such as off-target effects, biomarker limitations, and cellular heterogeneity underscore the need for precision medicine approaches. Finally, we propose future directions to harness senescence as a dynamic therapeutic target, offering transformative potential for cancer treatment.
细胞衰老在癌症生物学中是一把双刃剑,既是一种肿瘤抑制机制,也是恶性肿瘤的驱动因素。最初,衰老通过诸如癌基因诱导的衰老和DNA损伤反应等途径,阻止受损或表达癌基因的细胞增殖,从而起到保护屏障的作用。然而,衰老细胞中持续存在的衰老相关分泌表型和代谢重编程会营造一种促炎、免疫抑制的肿瘤微环境,推动癌症进展、治疗抵抗和转移。这篇综述系统地研究了衰老在各种癌症中的分子机制,涵盖消化、生殖、泌尿、呼吸、神经、血液、内分泌和皮肤系统,并阐明了其在肿瘤抑制和促进中依赖于背景的作用。我们重点介绍了开创性的治疗创新,包括精准衰老细胞清除剂、衰老相关分泌表型调节剂以及整合免疫疗法、代谢干预和表观遗传调节剂的联合策略。该综述还讨论了微环境重塑以及剖析衰老异质性的前沿技术、用于生物年龄预测的表观遗传时钟和调节衰老的微生物组工程。尽管这些方法前景广阔,但诸如脱靶效应、生物标志物局限性和细胞异质性等挑战凸显了精准医学方法的必要性。最后,我们提出了将衰老作为动态治疗靶点的未来方向,为癌症治疗提供了变革潜力。